https://orcid.org/0000-0001-9561-8767
References
- Arruda GV, Weber R. R d S, Bruno AC, Pavoni JF. 2020. The risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case. Int J Radiat Biol. 1–6.DOI:10.1080/09553002.2021.1846818
- Feinendegen LE, Pollycove M, Neumann RD. 2012. Hormesis by low dose radiation effects: low-dose cancer risk modeling must recognize up-regulation of protection. In: Therapeutic nuclear medicine. Berlin, Heidelberg: Springer. p. 789–805.
- Ghadimi-Moghadam A, Haghani M, Bevelacqua J, Jafarzadeh A, Kaveh-Ahangar A, Mortazavi S, Ghadimi-Moghadam A, Mortazavi S. 2020. COVID-19 tragic pandemic: concerns over unintentional “directed accelerated evolution” of novel Coronavirus (SARS-CoV-2) and introducing a modified treatment method for ARDS. J Biomed Phys Eng. 10:241.
- Pan H, Peto R, Karim QA, Alejandria M, Restrepo AMH, García CH, Kieny MP, Malekzadeh R, Murthy S, Preziosi M-P. 2020. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. medRxiv.
- Scott BR. 2008. It's time for a new low-dose-radiation risk assessment paradigm—one that acknowledges hormesis. Dose Response. 6(4):333–351.
- Sharma DN, Guleria R, Wig N, Mohan A, Rath GK, Subramani V, Bhatnagar S, Mallick S, Sharma A, Patil P. 2020. Low dose radiation therapy for COVID-19 pneumonia: a pilot study. medRxiv.
- Travis LB, Gospodarowicz M, Curtis RE, Aileen Clarke E, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, et al. 2002. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. JNCI. 94(3):182–192.